首页> 美国卫生研究院文献>World Journal of Gastroenterology >Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma
【2h】

Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma

机译:经皮肝定量乙醇注射液治疗肝癌的实验和临床评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To detect the relationship between absolute ethanol injection quantity, the interval and formation of fibreboard, the curative effect in treatment of hepatocarcinoma and to evaluate the clinical application of percutaneous hepatic quantified ethanol injection (PHQEI) in treatment of hepatic carcinoma (HCC).METHODS: (1) Experimental study: Twenty-four human hepatic carcinoma SMMC-7721 xenografted nude mice were randomly divided into three groups: Group A injected with quantified ethanol at short intervals (QESI), group B with quantified ethanol at long intervals (QELI) and group C with a small quantity of ethanol at long intervals (SQLI). The tumor tissues were sent for patho-histology and electron microscopic examinations. The diameters of tumors were measured with high frequency ultrasound before and after therapies and tumor growth index (TGI) was calculated. (2) Clinical study: Tumors of 122 cases of pathologically proved HCC were injected with quantified ethanol guided by ultrasound every 3-5 d 4-10 times per period of treatment. The quantity of ethanol was calculated according to the regressive equations where Y = 2.885X when the mass was ≤ 5 cm in diameter and Y = 1.805X when the mass was > 5 cm in diameter (X is the maximal diameter of the mass with the unit cm, Y is the ethanol quantity with the unit mL). The survival rates of 1, 2, 3 and 4 years and recurrent rates in situ as well as dystopia in the liver were calculated.RESULTS: (1) Experimental study: TGI of QESI group (0.072 ± 0.018) and QELI group (0.094 ± 0.028) was apparently lower than that of SQLI group (1.982 ± 0.482) (P < 0.01). TGI of QESI group seemed to be lower than that of QELI group, but it was not markedly different (P > 0.05) between two groups. Severe degeneration and necrosis could be seen in QESI group by patho-histology examination. Coagulative necrosis could be seen in most tumors of QESI group and there were no residual cancer cells under electronic microscope, while the residual cancer and inflammatory cells and fibre tissues could be seen around the tumors of QELI group. Infiltration of inflammatory cells could be seen and fibre tissues were formed. (2) Clinical study: B mode ultrasound showed that 62.5% of tumors shrank after PHQEI. The survival rates of 1, 2, 3 and 4 years of the group with tumors ≤ 3 cm in diameter were higher than those of the group with tumors > 3 cm in diameter. The recurrent rates of tumors in situ of the former group were apparently lower than those of the latter group. The recurrent rates of tumors in dystopia in the liver of the former group were markedly lower than those of the latter group. The 122 cases underwent a total of 1221 PEI. There were no complications such as hemorrhage and severe heart, liver and kidney functional injuries except for 1 case of melena and 4 cases of jaundice who recovered after 1-2 wk under common therapies.CONCLUSION: The experimental study shows quantified ethanol at intervals of 3-5 d could improve the curative effect of hepatocarcinoma. The clinical study shows PHQEI is an effective therapeutic method for HCC with few side-effects, and a low-cost. The treatment efficacy is more remarkable for tumors ≤ 3 cm in diameter.
机译:目的:探讨无水乙醇注射量,纤维板的间隔和形成,肝癌治疗效果之间的关系,并评价经皮肝定量乙醇注射液(PHQEI)在肝癌(HCC)治疗中的临床应用。方法:(1)实验研究:24只人肝癌SMMC-7721异种移植裸鼠随机分为三组:A组短时间间隔定量乙醇(QESI)注射,B组长间隔时间定量乙醇(QELI)注射。 ),并在C组中长时间间隔注入少量乙醇(SQLI)。将肿瘤组织送去进行病理组织学和电子显微镜检查。在治疗前后用高频超声测量肿瘤的直径,并计算肿瘤生长指数(TGI)。 (2)临床研究:经超声引导的定量乙醇每疗程3-5 d 4-10次,对122例经病理证实的HCC肿瘤注射定量乙醇。乙醇的含量是根据回归方程计算的,当质量小于或等于5厘米时,Y = 2.885X,质量大于或等于5 cm时,Y = 1.805X(X是质量最大且直径小于或等于5 cm时的最大直径)。单位是厘米,Y是单位为mL的乙醇量)。结果:(1)实验研究:QESI组(0.072±0.018)和QELI组(0.094±)的TGI。 0.028)明显低于SQLI组(1.982±0.482)(P <0.01)。 QESI组的TGI似乎低于QELI组,但两组之间没有显着差异(P> 0.05)。病理组织学检查发现QESI组严重变性和坏死。 QESI组大多数肿瘤均可见凝集性坏死,电镜下无残留癌细胞,而QELI组肿瘤周围可见残留癌,炎性细胞和纤维组织。可以看到炎性细胞的浸润并形成了纤维组织。 (2)临床研究:B超检查显示,PHQEI后肿瘤缩小了62.5%。直径≤3 cm的组的1、2、3和4年生存率高于直径≥3 cm的组。前一组的原位肿瘤复发率明显低于后一组。前一组肝脏反乌托邦的肿瘤复发率明显低于后一组。 122例患者接受了1221个PEI。结论:实验研究表明,每隔3个疗程进行一次定量乙醇检测,发现只有1例黑斑病和4例黄疸患者在1-2周后恢复,没有出血和严重的心,肝,肾功能损伤等并发症。结论: -5 d可以改善肝癌的疗效。临床研究表明,PHQEI是一种有效的肝癌治疗方法,副作用少,成本低。对于直径≤3 cm的肿瘤,治疗效果更为显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号